Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units.
Adverse drug events prevention
Drug incompatibilities
Intensive care unit
Intravenous therapy
Pharmacist
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
01
08
2018
accepted:
21
11
2018
pubmed:
14
12
2018
medline:
10
5
2019
entrez:
14
12
2018
Statut:
ppublish
Résumé
Physicochemical incompatibility (PCI) between drugs infused together is frequent, but under-recognized. PCI can lead to drug inactivity, catheter occlusion, embolism or inflammatory reactions. The aims of this work were to identify most frequent and relevant drug incompatibilities and to review and develop strategies for their prevention. This was an observational prospective survey conducted between January and March 2015 in an intensive care unit (ICU) and in September 2014 in a hematology sterile unit (HSU). Drugs administered to patients were recorded and their compatibility assessed based on published compatibility data. Drug incompatibilities accounted for 12% (23/189) and 17% (116/686) of drug pairs infused in the ICU and the HSU, respectively. Pantoprazole was the most frequent drug implied in PCI. Regarding drug classes, anti-infective agents and gastrointestinal drugs were the most frequently implied. Among the incompatible pairs, 78% and 61% implicated a drug with extreme pH in the ICU and HSU, respectively. The tools proposed to reduce the frequency of PCI included: compatibility cross-tables, labeling of drugs with extreme pH and optimized administration schedules. Given the frequency and the potential for severe consequences of PCI, pharmacists have a role to play in raising awareness of nurses and practitioners, and proposing adequate tools and solutions to reduce their incidence.
Identifiants
pubmed: 30543036
doi: 10.1007/s00228-018-2602-6
pii: 10.1007/s00228-018-2602-6
doi:
Substances chimiques
Pantoprazole
D8TST4O562
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-187Références
Am J Health Syst Pharm. 2000 Dec 15;57(24):2284-5
pubmed: 11146974
N Engl J Med. 2003 Mar 20;348(12):1123-33
pubmed: 12646670
Anaesthesist. 2003 May;52(5):409-12
pubmed: 12750824
Dig Dis Sci. 2003 Jul;48(7):1352-4
pubmed: 12870794
Anesth Analg. 2004 Jul;99(1):177-82
pubmed: 15281526
Nursing. 2005 Feb;35(2):26
pubmed: 15706259
Curr Opin Clin Nutr Metab Care. 2005 May;8(3):277-83
pubmed: 15809530
Drug Dev Ind Pharm. 2005 Dec;31(10):943-9
pubmed: 16316849
Mayo Clin Proc. 2006 Sep;81(9):1159-71
pubmed: 16970212
Expert Opin Drug Saf. 2008 Sep;7(5):515-23
pubmed: 18759704
Am J Health Syst Pharm. 2008 Oct 1;65(19):1834-40
pubmed: 18796425
Am J Health Syst Pharm. 2009 Feb 15;66(4):348-57
pubmed: 19202044
Am J Pharm Educ. 2007 Dec 15;71(6):122
pubmed: 19503706
Crit Care Med. 2010 Sep;38(9):1890-8
pubmed: 20562698
Intensive Care Med. 2012 Jun;38(6):1008-16
pubmed: 22527062
BMC Pediatr. 2013 Feb 06;13:21
pubmed: 23384207
Ann Pharmacother. 2013 May;47(5):637-43
pubmed: 23606550
Anaesth Crit Care Pain Med. 2015 Apr;34(2):83-8
pubmed: 25858619
Med Mal Infect. 2016 Jul;46(5):242-68
pubmed: 27112521
Rev Bras Ter Intensiva. 2016 Jun;28(2):147-53
pubmed: 27410410
Diabetes Care. 1987 May-Jun;10(3):348-51
pubmed: 3297580
Br Med J. 1974 Mar 2;1(5904):383-5
pubmed: 4819177
Am J Hosp Pharm. 1994 Jun 1;51(11):1427-8
pubmed: 7942876
JPEN J Parenter Enteral Nutr. 1996 Jan-Feb;20(1):81-7
pubmed: 8788269
Am J Health Syst Pharm. 1996 Dec 15;53(24):2990
pubmed: 8974165